An exceptional case of full-thickness macular hole closure in a patient with Behçet disease

Ocul Immunol Inflamm. 2014 Feb;22(1):79-81. doi: 10.3109/09273948.2013.829107. Epub 2013 Sep 24.

Abstract

Purpose: To present a case of a full-thickness macular hole closure in a patient with Behcet uveitis.

Design: A 23-year-old-male patient with Behcet Disease had clinically inactive uveitis with topical steroids, oral azathiopurine and cyclosporine until he developed a retinal infiltrate in the left eye which evolved into a full-thickness macular hole during the follow-up.

Methods: Strict control of inflammation and subsequent vitrectomy was planned. Meanwhile another attack of panuveitis developed in the left eye and subcutaneous Interferon alfa-2b interferon treatment was initiated.

Results: After 2 months, the patient was clinically inactive with complete closure of the macular hole.

Conclusions: Strict control of inflammation may result in closure of the macular hole and avoid the need for vitrectomy.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Administration, Topical
  • Azathioprine
  • Behcet Syndrome / complications*
  • Behcet Syndrome / diagnosis
  • Behcet Syndrome / drug therapy
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Male
  • Panuveitis / complications*
  • Panuveitis / diagnosis
  • Panuveitis / drug therapy
  • Recombinant Proteins / therapeutic use
  • Remission, Spontaneous
  • Retinal Perforations / etiology
  • Retinal Perforations / physiopathology*
  • Tomography, Optical Coherence
  • Visual Acuity / physiology
  • Young Adult

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Cyclosporine
  • Azathioprine